PMID- 25397514
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160121
LR  - 20181023
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 17
IP  - 4 Suppl 3
DP  - 2014
TI  - 144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 
      HIV-infected patients: data from the German STAR/STELLA cohort.
PG  - 19770
LID - 10.7448/IAS.17.4.19770 [doi]
LID - 19770 [doi]
AB  - INTRODUCTION: STAR/STELLA is a prospective[TS1] cohort of HIV patients initiated 
      on LPV/r-based ART in routine clinical practice. Here, virologic/immunologic 
      outcomes and safety data of LPV/r-based first-line ART over a period of 144 weeks 
      are presented. METHODS: Analysis included ART-naive patients who started on LPV/r 
      before July 2011 (i.e. patients with >/=144 weeks since ART initiation). Safety 
      evaluation included adverse events (AEs), discontinuations (disc.) due to AEs, 
      and symptoms assessed with the self-report ACTG Symptom Distress Module (ASDM; 
      high score=high distress). RESULTS: 1409 patients were included (84% men; 76% on 
      TDF+FTC), with a large proportion in advanced stages of HIV disease at ART 
      initiation: 48% had a CD4 count <200/microL, 55% had HIV RNA levels >100,000 c/mL. 
      53% of patients (n=746) remained on LPV/r for at least 144 weeks. Time on drug 
      was longer for patients initiated before 2008 than in subsequent years (HRadj, 
      1.2; 95% CI, 1.0-1.4; p=0.04; hazard ratio adjusted for CD4 <200/microL and HIV RNA 
      >100,000 c/mL). Main reasons for d/c were: AEs (19.3%), patient wish (9.2%), 
      virologic/immunologic failure (4.1%), and noncompliance (2.8%); 1.6% of patients 
      died. By week 144, 33% of patients had >750 CD4/microL (Kaplan-Meier estimate): time 
      to CD4 count >750 c/ microL, stratified by BL CD4 count, is shown in Figure 1. 
      CONCLUSION: In the STAR/STELLA observational cohort, LPV/r-based ART demonstrated 
      good virologic outcomes and immune recovery in ART-naive patients over 144 weeks, 
      with significant improvements in symptom distress. Over three years, <5% of 
      patients discontinued LPV/r due to virologic/immunologic failure, and 19% of 
      patients discontinued for tolerability reasons.
FAU - Wolf, Eva
AU  - Wolf E
AD  - HIV Research and Clinical Care Centre, MVZ Karlsplatz, Munich, Germany.
FAU - Trein, Andreas
AU  - Trein A
AD  - HIV Center (Drs A. Schaffert/E. Schnaitmann/A. Trein), Stuttgart, Germany.
FAU - Baumgarten, Axel
AU  - Baumgarten A
AD  - HIV Practice (Drs S. Dupke/A. Baumgarten/A. Carganico), Berlin, Germany.
FAU - Stephan, Christoph
AU  - Stephan C
AD  - HIV Center, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
FAU - Jaeger, Hans
AU  - Jaeger H
AD  - HIV Research and Clinical Care Centre, MVZ Karlsplatz, Munich, Germany.
FAU - Hillenbrand, Heribert
AU  - Hillenbrand H
AD  - MVZ PraxisCityOst (Drs. H. Hillenbrand, H. Karcher), Berlin, Germany.
FAU - Koeppe, Siegfried
AU  - Koeppe S
AD  - Gemeinschaftspraxis (Drs S. Koeppe/P. Kreckel), Berlin, Germany.
FAU - Lutz, Thomas
AU  - Lutz T
AD  - Infektiologikum Frankfurt-City, Frankfurt am Main, Germany.
FAU - Koenig, Bettina
AU  - Koenig B
AD  - Medical Department, AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany.
FAU - Stellbrink, Hans-Juergen
AU  - Stellbrink HJ
AD  - Study Center, Infektionsmedizinisches Centrum Hamburg, Hamburg, Germany.
LA  - eng
PT  - Journal Article
DEP - 20141102
PL  - Switzerland
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
PMC - PMC4225449
EDAT- 2014/11/15 06:00
MHDA- 2014/11/15 06:01
PMCR- 2014/11/02
CRDT- 2014/11/15 06:00
PHST- 2014/11/15 06:00 [entrez]
PHST- 2014/11/15 06:00 [pubmed]
PHST- 2014/11/15 06:01 [medline]
PHST- 2014/11/02 00:00 [pmc-release]
AID - 19770 [pii]
AID - 10.7448/IAS.17.4.19770 [doi]
PST - epublish
SO  - J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19770. doi: 10.7448/IAS.17.4.19770. 
      eCollection 2014.